| Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity F Zádor, D Kocsis, A Borsodi, S Benyhe Neurochemistry international 67, 14-22, 2014 | 33 | 2014 |
| Receptome: interactions between three pain-related receptors or the “Triumvirate” of cannabinoid, opioid and TRPV1 receptors F Zádor, M Wollemann Pharmacological research 102, 254-263, 2015 | 28 | 2015 |
| Design, Synthesis and Biological Evaluation of Two Opioid Agonist and Cav2.2 Blocker Multitarget Ligands A Mollica, R Costante, E Novellino, A Stefanucci, S Pieretti, F Zador, ... Chemical biology & drug design 86 (2), 156-162, 2015 | 28 | 2015 |
| Novel cyclic biphalin analogue with improved antinociceptive properties A Mollica, A Carotenuto, E Novellino, A Limatola, R Costante, F Pinnen, ... ACS medicinal chemistry letters 5 (9), 1032-1036, 2014 | 22 | 2014 |
| Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor … F Zádor, N Lénárt, B Csibrány, M Sántha, M Molnár, B Tuka, R Samavati, ... Neuropharmacology 89, 298-307, 2015 | 21 | 2015 |
| Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors A Mollica, S Pelliccia, V Famiglini, A Stefanucci, G Macedonio, ... Journal of enzyme inhibition and medicinal chemistry 32 (1), 444-451, 2017 | 20 | 2017 |
| A novel µ-opioid receptor ligand with high in vitro and in vivo agonist efficacy E Lacko, A Varadi, R Rapavi, F Zador, P Riba, S Benyhe, A Borsodi, ... Current medicinal chemistry 19 (27), 4699-4707, 2012 | 20 | 2012 |
| Biochemistry of opioid (morphine) receptors: Binding, structure and molecular modelling S Benyhe, F Zádor, F Ötvös Acta Biologica Szegediensis 59 (suppl. 1.), 17-37, 2015 | 18 | 2015 |
| Inhibition of forebrain μ-opioid receptor signaling by low concentrations of rimonabant does not require cannabinoid receptors and directly involves μ-opioid receptors F Zádor, F Ötvös, S Benyhe, A Zimmer, E Páldy Neurochemistry international 61 (3), 378-388, 2012 | 18 | 2012 |
| The peripheral versus central antinociception of a novel opioid agonist: acute inflammatory pain in rats M Balogh, ZS Zádori, B Lázár, D Karádi, S László, SA Mousa, S Hosztafi, ... Neurochemical research 43 (6), 1250-1257, 2018 | 15 | 2018 |
| Inhibition of opioid receptor mediated G-protein activity after chronic administration of kynurenic acid and its derivative without direct binding to opioid receptors F Zádor, R Samavati, E Szlávicz, B Tuka, E Bojnik, F Fulop, J Toldi, ... CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2014 | 14 | 2014 |
| Interactions between the kynurenine and the endocannabinoid system with special emphasis on migraine G Nagy-Grócz, F Zádor, S Dvorácskó, Z Bohár, S Benyhe, C Tömböly, ... International journal of molecular sciences 18 (8), 1617, 2017 | 13 | 2017 |
| Opioid receptor activity and analgesic potency of DPDPE peptide analogues containing a xylene bridge A Stefanucci, E Novellino, S Mirzaie, G Macedonio, S Pieretti, P Minosi, ... ACS medicinal chemistry letters 8 (4), 449-454, 2017 | 12 | 2017 |
| Further characterization of hemopressin peptide fragments in the opioid and cannabinoid systems E Szlavicz, PS Perera, C Tomboly, Z Helyes, F Zador, S Benyhe, ... Anesthesia & Analgesia 121 (6), 1488-1494, 2015 | 11 | 2015 |
| Evaluation of the analgesic effect of 4-anilidopiperidine scaffold containing ureas and carbamates L Monti, A Stefanucci, S Pieretti, F Marzoli, L Fidanza, A Mollica, S Mirzaie, ... Journal of Enzyme Inhibition and Medicinal Chemistry 31 (6), 1638-1647, 2016 | 10 | 2016 |
| Functional characterization of a novel opioid, PZM21, and its effects on the behavioural responses to morphine L Kudla, R Bugno, U Skupio, L Wiktorowska, W Solecki, A Wojtas, ... British Journal of Pharmacology 176 (23), 4434-4445, 2019 | 9 | 2019 |
| Cyclic biphalin analogues incorporating a xylene bridge: synthesis, characterization, and biological profile A Stefanucci, A Carotenuto, G Macedonio, E Novellino, S Pieretti, ... ACS medicinal chemistry letters 8 (8), 858-863, 2017 | 8 | 2017 |
| Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors S Dvorácskó, A Keresztes, A Mollica, A Stefanucci, G Macedonio, ... European Journal of Medicinal Chemistry 178, 571-588, 2019 | 7 | 2019 |
| New opioid receptor antagonist: Naltrexone-14-O-sulfate synthesis and pharmacology F Zádor, K Király, A Váradi, M Balogh, Á Fehér, D Kocsis, AI Erdei, ... European journal of pharmacology 809, 111-121, 2017 | 7 | 2017 |
| Kynurenic acid and its analogue can alter the opioid receptor G-protein signaling after acute treatment via NMDA receptor in rat cortex and striatum R Samavati, F Zádor, E Szűcs, B Tuka, D Martos, G Veres, R Gáspár, ... Journal of the Neurological Sciences 376, 63-70, 2017 | 7 | 2017 |
